GAMMA Investing LLC Acquires 231,951 Shares of Fresenius Medical Care AG (NYSE:FMS)

GAMMA Investing LLC increased its holdings in Fresenius Medical Care AG (NYSE:FMS - Free Report) by 3,237.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 239,115 shares of the company's stock after buying an additional 231,951 shares during the period. GAMMA Investing LLC's holdings in Fresenius Medical Care were worth $5,954,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Versant Capital Management Inc lifted its position in Fresenius Medical Care by 1,410.9% in the 1st quarter. Versant Capital Management Inc now owns 6,648 shares of the company's stock valued at $166,000 after purchasing an additional 6,208 shares during the last quarter. Forum Financial Management LP bought a new stake in Fresenius Medical Care in the 4th quarter valued at about $247,000. Vident Advisory LLC raised its position in shares of Fresenius Medical Care by 11.8% during the 4th quarter. Vident Advisory LLC now owns 23,410 shares of the company's stock worth $530,000 after buying an additional 2,464 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Fresenius Medical Care during the 4th quarter worth about $290,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Fresenius Medical Care during the 4th quarter worth about $850,000. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care Price Performance

FMS stock traded down $0.34 on Friday, hitting $28.60. 253,634 shares of the company's stock traded hands, compared to its average volume of 334,222. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $30.46. The stock has a market cap of $16.78 billion, a price-to-earnings ratio of 23.64, a P/E/G ratio of 0.76 and a beta of 0.88. The stock has a fifty day moving average of $26.69 and a 200-day moving average of $24.68. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.43 by $0.01. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The business had revenue of $5.54 billion during the quarter, compared to analyst estimates of $4.71 billion. On average, analysts forecast that Fresenius Medical Care AG will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care Increases Dividend

The firm also recently announced an annual dividend, which was paid on Friday, June 6th. Investors of record on Friday, May 23rd were paid a dividend of $0.7871 per share. The ex-dividend date was Friday, May 23rd. This is a positive change from Fresenius Medical Care's previous annual dividend of $0.44. This represents a yield of 1.9%. Fresenius Medical Care's dividend payout ratio is currently 50.89%.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Morgan Stanley restated an "underweight" rating on shares of Fresenius Medical Care in a research report on Thursday, May 15th. Truist Financial boosted their price target on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the stock a "hold" rating in a research report on Monday, May 12th. Finally, Wall Street Zen assumed coverage on shares of Fresenius Medical Care in a research report on Tuesday, May 20th. They set a "strong-buy" rating on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $27.80.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.